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ABSTRACT
Among men in South Africa, the prevalence of tobacco smoking is as high
as 33%. Although smoking is responsible for most lung cancer in South
Africa, occupational and environmental exposures contribute greatly to
risk. We conducted a tobacco and lung cancer screening needs
assessment and administered surveys to adults who smoked >100
cigarettes in their lifetime in Johannesburg (urban) and Kimberley (rural).
We compared tobacco use, risk exposure, attitudes toward and
knowledge of, and receptivity to cessation and screening, by site. Of 324
smokers, nearly 85% of current smokers had a <30 pack-year history of
smoking; 58.7% had tried to stop smoking ≥1 time, and 78.9% wanted
to quit. Kimberley smokers more often reported being advised by a
healthcare provider to stop smoking (56.5% vs. 37.3%, p=0.001) than
smokers in Johannesburg but smokers in Johannesburg were more
willing to stop smoking if advised by their doctor (72.9% vs. 41.7%,
p<0.001). Findings indicate that tobacco smokers in two geographic
areas of South Africa are motivated to stop smoking but receive no
healthcare support to do so. Developing high risk criteria for lung cancer
screening and creating tobacco cessation infrastructure may reduce
tobacco use and decrease lung cancer mortality in South Africa.
ARTICLE HISTORY
Received 20 January 2020
Accepted 10 April 2020
KEYWORDS
Tobacco smoking; Tobacco




Lung cancer is the leading cause of cancer death worldwide (Bray et al., 2018). In South Africa (SA),
lung cancer is the number one cause of cancer mortality among men and the third most common
cause of cancer mortality among women (Cancer Association of South Africa (CANSA), 2014).
About 60% of South African lung cancer deaths are attributable to smoking tobacco (Sitas et al.,
2004). The prevalence of smoking in South Africa among all adults is 17.6% with rates as high as
33% among males and 33% in the Western Cape (Reddy et al., 2015; World Bank Group, 2019).
Although smoking is responsible for most lung cancer cases, occupational exposure to uranium,
ionising radiation, asbestos, silica, arsenic, beryllium, chloromethyl, and nickel chromates associated
with mining and indoor emissions, and polycyclic aromatic hydrocarbons (PAHs) from burning
fuels to cook, are also known to cause lung cancer (Bello et al., 2011; Driscoll et al., 2005; Siemiatycki
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et al., 2004). Nearly 500,000 people are employed in SA mines (Chamber of Mines of South Africa,
2020), and about 18% of the population uses biomass energy for cooking (Statistics South Africa).
Infection with tuberculosis (TB) or human immunodeficiency virus (HIV) further contributes to
lung cancer incidence in South Africa, which has one of the highest burdens of TB and HIV in the
world (van Zyl-Smit et al., 2013). Approximately 19% of adults aged 15–49 years in South Africa are
infected with HIV (Statistics South Africa, 2016) and 80% of the population is believed to be infected
with TB, most of which are latent infections among adults 30–39 years (TBFacts.org, 2019). Lung
cancer is the leading non-AIDS defining cancer and is the most common cause of cancer related
death among HIV infected individuals (Moltó et al., 2015; Morlat et al., 2014; Shiels et al., 2011; Win-
stone et al., 2013). While higher smoking rates among those infected with HIV increase their lung
cancer risk, HIV positivity, independent of smoking status, also is associated with lung cancer risk
(Sigel et al., 2012; Sigel et al., 2017). The relationship between Infection with tuberculosis and lung
cancer has long been debated but there is evidence to support that latent or previous history of TB
increases risk for lung cancer (Brenner et al., 2011; Keikha & Esfahani, 2018). Patients with TB were
found to be 10.9 times more likely than others to develop lung cancer (Yu et al., 2011), and smoking
exacerbates the risk.
The most effective way for smokers to reduce their risk of lung cancer is tobacco cessation. A
study conducted in the United States among more than 200,000 individuals reported that tobacco
cessation by the age of 40 years reduced mortality associated with continued smoking by nearly
90%, and that cessation before age 65 reduced the excess risk of death by two-thirds (Jha et al.,
2013). Daily smoking prevalence is highest among Coloured (i.e. individuals of mixed African
and European or Asian ancestry) and Indian/Asian men and prevalence among Coloured
women is much higher (12-fold higher) than among other women (Alcohol Tobacco and
Other Drug Research Unit and South African Medical Research Council, 2016). Despite ratifica-
tion of Article 14 of the World Health Organization Framework Convention on Tobacco Control
(WHO FCTC) (World Health Organization (WHO), 2010) mandating that local healthcare sys-
tems in South Africa identify tobacco users and refer them to treatment (Alcohol Tobacco and
Other Drug Research Unit and South African Medical Research Council, 2016; Omole et al.,
2010), no systems have yet implemented that mandate. Few counsellors/specialists had been
trained to treat tobacco addiction in South Africa and they are available primarily in mental
health facilities (Alcohol Tobacco and Other Drug Research Unit and South African Medical
Research Council, 2016). A single dedicated smoking cessation clinic in Cape Town is the
only clinical service and training centre for tobacco treatment in the country (Tadzimirwa
et al., 2019).
Population-based lung cancer screening using low-dose computed tomography (LDCT) also can
reduce lung cancer mortality based on the landmark National Lung Screening Trial (NLST), which
demonstrated a 20% reduction in lung cancer mortality among high-risk individuals (National Lung
Screening Trial Research et al., 2011). In 2015, the European Society of Radiology and the European
Respiratory Society issued a white paper with lung cancer screening recommendations like that
issued by the United States Preventive Services Task Force, recommending LDCT among high-
risk individuals, defined as current or former (quit within the past 15 years) smokers aged 55–80
years with a 30 pack-year history of tobacco use (Kauczor et al., 2015). South Africa has recently
issued a similar statement on lung cancer screening (Koegelenberg et al., 2019). Uptake of LDCT
in high-income countries with the resources to implement population-based lung cancer screening
is low (Li et al., 2018; Rai et al., 2019). In low and middle income countries challenged with establish-
ing the necessary infrastructure to support LDCT lung cancer screening, training healthcare person-
nel, and developing referral algorithms, LDCT screening is practically non-existent (Pinsky, 2018;
Raez et al., 2018; Shankar et al., 2019). Instead, tobacco control and prevention strategies used in
smoking cessation programmes will likely be the most important interventions for decreasing
lung cancer morbidity and mortality in developing countries at this time (Raez et al., 2018; Shankar
et al., 2019).
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The Bristol Myers Squibb Foundation–funded Wits Health Consortium Centre of Respiratory
Excellence Gauteng (CORE) linked to the University of Witwatersrand (Wits) in Johannesburg,
South Africa, is a member of a multi-national research programme in sub-Saharan Africa with over-
arching goals to improve the early detection, management, and outcomes of lung cancer for the
region. In line with these goals, our research team at the Herbert Irving Comprehensive Cancer Cen-
ter (HICCC) of Columbia University in New York, U.S.A., partnered with CORE researchers to
examine patterns of tobacco use, exposure to lung cancer risk factors, attitudes and knowledge
about lung cancer, tobacco cessation, and lung cancer screening among adult current and former
smokers. Findings generated from this preliminary study will inform future community-based inter-
ventions that can be tested in both urban and rural South African settings to decrease lung cancer




This pilot study was conducted in two CORE sites: Johannesburg, the largest city in South Africa,
and Kimberley, a rural diamond mining community in the Northern Cape province of SA. In Johan-
nesburg, recruitment was conducted in primary level clinics within the referral networks of the three
Wits-associated tertiary hospitals: Charlotte Maxeke Johannesburg Academic Hospital, Helen
Joseph Hospital, and Chris Hani Baragwanath Academic Hospital in Soweto and western suburbs
of Johannesburg. In Kimberley, participants were recruited at clinics at the Kimberley Hospital
and Dr. Harry Surtie Hospital in Upington, and Kuruman Hospital, affiliated with the Kimberley
Hospital Complex (KHC) in the Northern Cape Province.
Participants
Adults aged 20–80 years who had never been diagnosed with lung cancer and who reported having
smoked at least 100 cigarettes in their lifetime were invited to participate in this study. With the per-
mission of the medical director at each recruitment clinic, multilingual study team nurses trained in
the conduct of human subject research identified study-eligible individuals, obtained written
informed consent, and conducted face-to-face interviews that were approximately 15 min in
duration.
Survey
Sociodemographic, health-related, and tobacco smoking characteristics, exposure to occupational
and residential environmental risk factors, and knowledge of and attitudes toward tobacco cessation
and lung cancer screening were evaluated. Participant demographics included age (based on actual
or estimated date of birth), sex, and racial group (White, Black, Coloured, or Asian). Literacy level
was assessed by asking ‘Can you read?’ (‘Yes’, ‘No’, or ‘A little bit’.) Also assessed were educational
attainment, medical insurance coverage, and employment status. Participants were further asked
about their health status (excellent, good, fair, poor, or bad) and existing comorbidities (heart dis-
ease, hypertension, chronic bronchitis, asthma, TB, HIV/AIDS, and cancer).
Tobacco use history was obtained by asking participants about their current smoking status (cur-
rent or former cigarette smoker). Additional questions assessed use of e-cigarettes or vaping, oka
(hookah) pipe, tobacco chew or snuff, and tobacco pipe or cigars. For both current and former smo-
kers, age when started smoking, the number of years smoking, and the number of cigarettes smoked
per day were determined. Pack history was calculated using the number of cigarettes smoked per day,
divided by 20, and multiplied by the number of years smoking for current smokers. Current and
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former smokers were also asked whether or not a healthcare provider had ever spoken to them or
recommended that they quit smoking; had ever given them a prescription for medication (Champix)
to quit smoking, suggested nicotine replacement therapy (nicotine patch or gum), or referred them
to a smoking cessation ‘quitline’ for help to stop smoking. Among current smokers, to assess level of
nicotine addiction, we asked how soon after waking they had their first cigarette, the number of pre-
vious quit attempts, and whether or not they wanted to stop smoking.
Environmental exposures were grouped as residential and occupational. Residential exposures
included whether or not wood, coal, or animal dung was burned indoors for cooking, heating, or
lighting; the type of cooking facility available in the home (gas stove, paraffin/gel stove, coal/wood
stove, electric stove/hot plate, or open fire), and where cooking is done (mainly inside, mainly out-
side, inside and outside). Environmental exposures to asbestos, radon and radioactive gas and heavy
dust in the air, heavy air pollution from diesel engines or generators or car exhaust fumes, and
second-hand smoke exposure in the home or at work were determined with Yes/No responses.
Questions about occupational exposures included ever working in the mining (arsenic/gold, asbes-
tos, diamond, gold, platinum, copper, coal, rare metals), building and construction, and scrap yard,
or metal recycling industries.
Knowledge of lung cancer risk factors was assessed by asking participants if they agreed or dis-
agreed that lung cancer risks were associated with: cigarette smoking; second-hand cigarette
smoke exposure; exposure to radon gas or other chemicals like asbestos and silica; air pollution;
lung disease such as COPD, being HIV positive; or having TB. To assess lung cancer risk perceptions,
participants were asked ‘How common do you think lung cancer is?’, ‘How serious do you think lung
cancer is?’, ‘Do you worry about getting lung cancer?’ and ‘What do you think your chances of get-
ting lung cancer are?’ (Park et al., 2014).
Receptivity to tobacco cessation and treatment and lung cancer screening with low-dose com-
puted tomography (LDCT) were examined. Participants were presented with a series of scenarios
in which one might consider tobacco cessation. These included: if your doctor recommended it, if
Champix (nicotinic agonist medication) was free, if you had symptoms of lung cancer, if your family
wanted you to, and if cessation support was available. Responses included ‘Yes, definitely’, ‘Maybe’,
and ‘Definitely not’. To evaluate attitudes and beliefs toward LDCT screening for lung cancer, the
interviewer first read a brief description of LDCT that included how the test is performed, the use
of low-dose radiation, the need to find tumours when they are small, the possibility of incidental
findings, and the current criteria for LDCT lung cancer screening. Following this description, current
smokers were asked if they would have LDCT to screen for lung cancer if the doctor recommended
it, or if they thought they had symptoms of lung cancer. They were also asked if they feared that
LDCT would find lung cancer, if the test would cause them worry, and if they would want to find
lung cancer early if it was present.
Data analysis
Responses were recorded in a RedCap database (Harris et al., 2009; Harris et al., 2019) by the study
coordinator at each site. De-identified survey data were transmitted to the Columbia researchers for
analysis. All procedures were reviewed and approved by the Columbia University Institutional
Review Board and the University of Witwatersrand Ethics Committee. We conducted descriptive
analyses including frequency distributions, means, and univariable analyses using chi-square tests
to evaluate differences in demographics, health-related and smoking use characteristics, environ-
mental risk factors, and knowledge of and attitudes toward tobacco cessation and lung cancer screen-
ing. Normal distribution of continuous variables was assessed with the Shapiro Wilk test. The
difference in the means of normally distributed continuous variables was calculated using Student’s
t test and, for non-parametrically distributed continuous variables, using the Mann–Whitney U test.
P-values less than 0.05 were considered statistically significant, and all analyses were conducted using
IBM SPSS, version 26 (IBM Corp., 2019).
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Results
In total, 324 current and former smokers (who had smoked more than 100 cigarettes in their life-
time) completed the survey; 182 (56.2%) at the Johannesburg sites and 142 (43.8%) at the sites in
Kimberley (Table 1). The mean age of all participants was 44.7 [SD 15.2] years; 70.4% were male,
and 71.9% were Black. A majority were at least high school educated (81.8%), but nearly half
(48.5%) were unemployed. The most commonly reported comorbidities were hypertension
(25.6%) and HIV/AIDS (15.4%). Nearly 87% of the participants were current smokers and slightly
more than half reported using e-cigarettes or vaping (52.2%). Participants from urban Johannesburg,
more often reported having HIV/AIDS (24.2% vs. 4.2%, p <0.001) and using e-cigarettes and vaping
(65.4% vs. 35.2%, p <0.001) than did participants in the rural Kimberley area.
Among current smokers, the mean age at initiation of smoking was 18.0 years [SD 5.9] and the
mean number of years smoking was 25.4 [SD 13.8] (Table 1). The mean number of pack years (num-
ber of cigarettes smoked per day multiplied by the number of years smoking) was 15.5 [SD15.4]. The
majority of current smokers reported wanting to quit (78.9%) but less than half (45.2%) had ever had
a conversation with their doctor about quitting. Compared to current smokers in Johannesburg, cur-
rent smokers in Kimberley more often reported ≥30 pack-years history of smoking (19.1% vs. 9.6%,
p = 0.03) and twice as frequently reported more than 4 quit attempts (24.3% vs. 12.7%, p = 0.04).
Current smokers in Kimberley also more often reported that a doctor spoke with them about quit-
ting (56.5% vs. 37.3%, p = 0.001) and offered nicotine replacement therapy (15.7% vs. 3.6%, p <0.001)
or referred them to a quitline for help quitting smoking (14.8% vs. 3.6%, p = 0.001). Current smokers
in Johannesburg however, reported more often smoking their first cigarette within 5 min of waking,
demonstrating a higher level of nicotine addiction (47.0% vs. 30.4%, p = 0.008) and more often
reported wanting to quit (83.7% vs. 71.9%, p = 0.02).
Although current and former smokers in Kimberley more often reported working in the mines
(11.3% vs. 4.4%, p = 0.019), Johannesburg participants claimed greater environmental exposures
to lung cancer risk factors at home and at work (Table 2). Residential exposures to chemicals and
pollutants were high in both communities but, in Johannesburg, significantly more smokers lived
in a home where wood, coal, or animal dung was used for heat or light; worked in the cement or
building industry, were exposed to asbestos or radon gas, or lived or worked in an area with
heavy air pollution from diesel generators or engines and second-hand smoke.
Overall, knowledge of lung cancer risk factors ranged from 85.2% for cigarette smoking to
46.9% for having HIV infection (Table 3). Participants from Johannesburg were far more
aware of lung cancer risk factors than those in Kimberley. For example, 92.3% of smokers in
Johannesburg but only 76.1% in Kimberley agreed that cigarette smoking was a lung cancer
risk factor (p <0.001). Attitudes and beliefs about how common and serious lung cancer is
also varied by site; more respondents in Johannesburg believed that lung cancer is ‘very common’
(61.0% vs. 49.3%, p = 0.01) worried about getting lung cancer ‘all the time’ (40.7% vs. 26.8%, p =
0.018), or believed they have a 50/50 chance of getting lung cancer (63.2% vs. 35.2%, p <0.001)
than Kimberley participants. Johannesburg current smokers were also more receptive to the ideas
of undergoing tobacco cessation and lung cancer screening than current smokers in Kimberley.
More Johannesburg than Kimberley smokers responded ‘Yes, definitely’ to questions about will-
ingness to quit if the healthcare provider told you to quit, if you could obtain free Champix, if
you had symptoms, and if support was available. More current smokers in Johannesburg than in
Kimberley also responded ‘Yes, definitely’ to having an LDCT to screen for lung cancer if the
healthcare provider recommended it and if they had any symptom of cancer. Although more
Johannesburg than Kimberley participants reported that the LDCT would cause them to
worry, participants in Johannesburg reported being less afraid of the test finding lung cancer
(77.7% vs. 64.3%, p = 0.042) and more of them wanted to know early if lung cancer was present
(95.2% vs. 87.0%, p = 0.038).
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Table 1. Demographic, health-related, and tobacco use characteristics of current and former tobacco smokers in urban






(n = 142) P value
Demographics
Age (years) 0.038
Mean [SD] 44.7 [15.2] 43.0 [14.4] 46.9 [15.8]
Range 20–85 20–85 20–78
Gender <0.001
Male 228 (70.4) 145 (79.7) 83 (58.5)
Female 96 (29.6) 37 (20.3) 59 (41.5)
Race <0.001
White 16 (4.9) 12 (6.6) 4 (2.8)
Black 233 (71.9) 159 (87.4) 74 (52.1)
Coloured 75 (23.1) 11 (6.0) 64 (45.1)
Asian 0 (0.0) 0 (0.0) 0 (0.0)
Ability to read 0.15
Yes 298 (92.3) 171 (94.0) 127 (89.4)
No 13 (4.0) 4 (2.2) 9 (6.3)
A little bit 12 (3.7) 6 (3.3) 6 (4.2)
Education 0.70
No formal education 12 (3.7) 4 (2.2) 8 (5.6)
Primary school 46 (14.2) 20 (11.0) 26 (18.3)
High school/tech school 226 (69.8) 136 (74.7) 90 (63.4)
University/college 39 (12.0) 21 (11.5) 18 (12.7)
Pay for medical care <0.001
Government 254 (78.6) 152 (83.5) 102 (71.8)
Medical aid 24 (7.4) 6 (3.3) 18 (12.7)
Self pay 41 (12.6) 23 (12.6) 18 (12.6)
Other 4 (1.2) 0 (0.0) 4 (2.8)
Employment 0.20
Full time 61 (18.8) 36 (19.8) 25 (17.6)
Part time 46 (14.2) 29 (15.9) 17 (12.0)
Unemployed 157 (48.5) 88 (48.4) 69 (48.6)
Self employed 17 (5.2) 12 (6.6) 5 (3.5)
Other 43 (13.3) 17 (9.3) 26 (18.3)
Health related characteristics
Health status 0.001
Excellent 58 (17.9) 28 (15.4) 30 (21.1)
Good 123 (38.0) 58 (31.9) 65 (45.8)
Fair 100 (30.9) 66 (36.3) 34 (23.9)
Poor 37 (11.4) 24 (13.2) 13 (9.2)
Bad 6 (1.9) 6 (3.3) 0 (0.0)
Comorbidities
Hypertension 83 (25.6) 50 (27.5) 33 (23.2) 0.37
Heart disease 13 (4.0) 3 (1.6) 10 (7.0) 0.015
Chronic bronchitis 16 (4.9) 10 (5.5) 6 (4.2) 0.59
Asthma 21 (6.5) 11 (6.0) 10 (7.0) 0.73
Tuberculosis
Current infection 18 (5.6) 11 (6.0) 7 (4.9) 0.65
Past infection 32 (9.9) 20 (11.0) 12 (8.5)
HIV/AIDS 50 (15.4) 44 (24.2) 6 (4.2) <0.001




Former smoker 43 (13.3) 16 (8.8) 27 (19.0)
Current smoker 281 (86.7) 166 (91.2) 115 (81.0)
e-Cigarettes or vaping 169 (52.2) 119 (65.4) 50 (35.2) <0.001
Oka (Hookah) pipe 46 (14.2) 21 (11.5) 25 (17.6) 0.21
Chew or snuff 5 (1.5) 3 (1.6) 2 (1.4) 0.86
Tobacco pipe or cigars 68 (21.0) 40 (22.0) 28 (19.7) 0.60
Current smoker
Age at initiation of smoking (years) 0.79
Mean [SD] 18.0 [5.9] 17.6 [5.6] 17.8 [6.0]
(Continued )
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Discussion
This study is the first to evaluate attitudes, knowledge, and behaviours surrounding tobacco use
among individuals in two different geographic locations in South Africa who have smoked more
than 100 cigarettes in their lifetime and to assess differences by urban vs. rural locale. We found
that smokers in both the urban and rural areas had a strong desire to stop smoking and had
attempted to quit tobacco in the past but lacked support from the medical community in the
form of screening for tobacco use or advice to stop cigarette smoking. The missed screening and
counselling opportunities found in our study confirm the findings of Omole et al. that, in exit inter-
views following a primary healthcare provider visit among 500 South African adults, only 12.9% were
screened for tobacco use and, of current smokers, 11.9% were advised against tobacco use (Omole
et al., 2010).
We also found that smokers at both sites were favourably disposed toward tobacco cessation
counselling, nicotine replacement therapy, nicotinic receptor agonist medication (e.g. Champix),
and even lung cancer screening with LDCT. These attitudes may reflect knowledge regarding the
lung cancer risk factors in the environment (both residential and occupational), overestimation of
lung cancer risk, or excessive worry about developing lung cancer in the future. Other findings of







(n = 142) P value
Range 8–66 8–66 9–56
Number of years smoking 0.94
Mean [SD] 25.4 [13.8] 24.4 [13.4] 27.1 [14.1]
Range 2–65 2–65 2–63
Number of cigarettes per day 0.10
Mean [SD] 11.2 [7.4] 10.9 [6.1] 11.6 [9.0]
Range 0–60 2–35 0–60
Pack years
Mean [SD] 15.5 [15.4] 13.9 [12.5] 17.6 [18.5] 0.29
Range 0.3–105 0.3–74 0.3–105
Heavy smoker pack years 0.03
<30 237 (84.3) 145 (87.3) 92 (80.0)
≥30 38 (13.5) 16 (9.6) 22 (19.1)
Missing 6 (2.1) 5 (3.0) 1 (0.9)
First cigarette how soon after waking 0.008
Within 5 min 113 (40.2) 78 (47.0) 35 (30.4)
6–30 min 74 (26.3) 43 (25.9) 31 (27.0)
After 30 min 94 (33.5) 45 (27.1) 49 (42.6)
How many times have you tried to quit 0.04
None 116 (41.3) 67 (40.6) 49 (42.4)
1–2 times 89 (1.8) 59 (35.8) 30 (26.1)
3–4 times 26 (9.3) 18 (10.9) 8 (7.0)
More than 4 times 49 (17.5) 21 (12.7) 28 (24.3)
Want to quit 0.02
Yes 221 (78.9) 139 (83.7) 82 (71.9)
No 59 (21.1) 27 (16.3) 32 (29.1)
Doctor ever talked to you or recommended you quit smoking 0.001
Yes 127 (45.2) 62 (37.3) 65 (56.5)
No 154 (54.8) 104 (62.7) 50 (43.5)
Doctor ever prescribed medicine (Champix) to help you quit 0.25
Yes 23 (8.2) 11 (6.6) 12 (10.4)
No 258 (91.8) 155 (93.4) 103 (89.6)
Doctor ever recommended nicotine patch or gum <0.001
Yes 24 (8.5) 6 (3.6) 18 (15.7)
No 257 (91.5) 160 (96.4) 97 (84.3)
Doctor ever recommended calling a quitline for help quitting 0.001
Yes 23 (8.2) 6 (3.6) 17 (14.8)
No 258 (91.8) 160 (96.4) 98 (85.2)
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lung cancer, unexpectedly high reported use of vaping with e-cigarettes, and low pack-year history of
cigarette smoking.
The urban Johannesburg respondents reported poorer health status overall; 24.2% stated that they
were HIV-positive, compared to 4.2% of rural Kimberley respondents. Knowledge of lung cancer risk
factors was consistently greater among the Johannesburg participants but neither group had a good
grasp of the associations of HIV and TB with the development of lung cancer. Greater knowledge of
lung cancer risk in the urban Johannesburg area may reflect more frequent contact with the









Ever lived where wood, coal, or animal dung was burned
indoors for cooking, heating, or lighting
0.004
Yes 174 (53.7) 110 (60.4) 64 (45.1)
No 144 (44.4) 68 (37.4) 76 (53.5)
Missing 6 (1.9) 4 (2.2) 2 (1.4)
Type of cooking facility 0.27
Gas stove 7 (2.2) 4 (2.2) 3 (2.1)
Paraffin/gel stove 8 (2.5) 4 (2.2) 4 (2.4)
Coal/wood stove 9 (2.8) 2 (1.1) 7 (4.9)
Electric stove 297 (91.7) 171 (94.0) 126 (88.7)
Open fire 3 (0.9) 1 (0.5) 2 (1.4)
Where cooking is done 0.06
Mainly inside 304 (93.8) 174 (95.6) 130 (91.5)
Mainly outside 2 (0.6) 0 (0.0) 2 (1.4)
Inside and outside 16 (4.9) 6 (3.3) 10 (7.0)
Exposed to asbestos <0.001
Yes 90 (27.8) 79 (43.4) 11 (7.7)
No 234 (72.2) 103 (56.6) 131 (92.3)
Exposed to radon/radioactive gas <0.001
Yes 61 (18.8) 52 (28.6) 9 (6.3)
No 263 (81.2) 130 (71.4) 133 (93.7)
Lived or worked with dust in the air <0.001
Yes 159 (49.1) 117 (64.3) 42 (29.6)
No 165 (50.9) 65 (35.7) 100 (70.4)
Lived or worked with heavy air pollution from diesel engines/
generators
<0.001
Yes 104 (32.1) 76 (41.8) 28 (19.7)
No 220 (67.9) 106 (58.2) 114 (80.3)
Second-hand smoke <0.001
Yes 255 (78.7) 156 (85.7) 99 (69.7)
No 69 (21.3) 26 (14.3) 43 (30.3)
Occupational
Worked in the mining industry 0.019
Yes 24 (7.4) 8 (4.4) 16 (11.3)
No 300 (92.6) 174 (95.6) 126 (88.7)
Arsenic/gold 1 (0.3) 1 (0.5) 0 (0.0) 0.28
Asbestos 1 (0.3) 0 (0.0) 1 (0.7) 0.20
Coal 2 (0.6) 2 (1.1) 0 (0.0) 0.13
Copper 4 (1.2) 0 (0.0) 4 (2.8) 0.01
Diamond 13 (4.0) 3 (1.6) 10 (7.0) 0.014
Gold 1 (0.3) 1 (0.5) 0 (0.0) 0.28
Platinum 4 (1.2) 3 (1.6) 1 (0.7) 0.43
Rare metals 0 (0.0) 0 (0.0) 0 (0.0) 1.00
Worked in cement, building industry 0.002
Yes 102 (31.5) 70 (38.5) 32 (22.5)
No 222 (68.5) 112 (61.5) 110 (75.5)
Worked in scrap yard/metal recycling 0.36
Yes 23 (7.1) 15 (8.2) 8 (5.6)
No 301 (92.9) 167 (91.8) 134 (94.4)
1544 G. C. HILLYER ET AL.
Table 3. Lung cancer risk knowledge, attitudes, and beliefs among current and former smokers urban Johannesburg and rural
Kimberley in South Africa.
Total (n = 324) Johannesburg (n = 182) Kimberley (n = 142) P value
Lung cancer risk knowledge
Cigarette smoking 276 (85.2) 168 (92.3) 108 (76.1) <0.001
Second-hand cigarette smoke 269 (83.0) 160 (87.9) 109 (76.8) 0.008
Exposure to radon 196 (60.5) 131 (72.0) 65 (45.8) <0.001
Exposure to chemicals 243 (75.0) 153 (84.1) 90 (63.4) <0.001
Air pollution 249 (76.9) 147 (80.8) 102 (71.8) 0.06
Lung disease 192 (59.4) 133 (73.1) 59 (41.5) <0.001
HIV positive 152 (46.9) 104 (57.1) 48 (33.8) <0.001
Tuberculosis 212 (65.8) 139 (76.4) 73 (51.4) <0.001
Lung cancer beliefs and attitudes
How common is lung cancer 0.01
Not very common 19 (5.9) 7 (3.8) 12 (8.5)
Somewhat common 75 (23.1) 45 (24.7) 30 (21.1)
Very common 181 (55.9) 111 (61.0) 70 (49.3)
Don’t know 49 (15.1) 19 (10.4) 30 (21.1)
How serious is lung cancer 0.25
Not very serious 10 (3.1) 4 (2.2) 6 (4.2)
Somewhat serious 33 (10.2) 15 (8.2) 18 (12.7)
Very serious 256 (79.0) 151 (83.0) 105 (73.9)
Don’t know 25 (7.7) 12 (6.6) 13 (9.2)
Worry about lung cancer 0.018
Never 56 (17.3) 25 (13.7) 31 (21.8)
Sometimes 156 (48.1) 83 (45.6) 73 (51.4)
All the time 112 (34.6) 74 (40.7) 38 (26.8)
Your chances of getting lung cancer <0.001
No chance 19 (5.9) 6 (3.3) 13 (9.2)
Probably will NOT get 16 (4.9) 5 (2.7) 11 (7.7)
50/50 chance 165 (50.9) 115 (63.2) 50 (35.2)
Definitely will get 48 (14.8) 30 (16.5) 18 (12.7)
Don’t know 54 (16.7) 18 (9.9) 36 (25.4)
Missing 22 (6.8) 8 (4.4) 14 (9.9)
Receptiveness to tobacco cessation and treatment
Quit if doctor told you to <0.001
Yes, definitely 169 (60.1) 121 (72.9) 48 (41.7)
Maybe 86 (30.6) 33 (19.9) 53 (46.1)
Definitely not 26 (9.3) 12 (7.2) 14 (12.2)
Quit with free Champix <0.001
Yes, definitely 220 (78.3) 147 (88.6) 73 (63.5)
Maybe 44 (15.7) 16 (9.6) 28 (24.3)
Definitely not 17 (6.0) 3 (1.8) 14 (12.2)
Quit if had symptoms of lung cancer <0.001
Yes, definitely 217 (77.2) 146 (88.0) 71 (61.7)
Maybe 52 (18.5) 17 (10.2) 35 (30.4)
Definitely not 12 (4.3) 3 (1.8) 9 (7.8)
Quit if family wanted you to 0.96
Yes, definitely 114 (40.6) 67 (40.4) 47 (40.9)
Maybe 121 (43.1) 71 (42.8) 50 (43.5)
Definitely not 46 (16.4) 28 (16.9) 18 (15.7)
Quit if support available <0.001
Yes, definitely 192 (68.3) 133 (80.1) 59 (51.3)
Maybe 60 (21.4) 23 (13.9) 37 (32.2)
Definitely not 29 (10.3) 10 (6.0) 19 (16.5)
LDCT lung cancer screening attitudes
LDCT if doctor recommended 0.001
Yes, definitely 246 (87.5) 155 (93.4) 91 (79.1)
Maybe 27 (9.6) 10 (6.0) 17 (14.8)
Definitely not 8 (2.8) 1 (0.6) 7 (6.1)
LDCT if had a LC symptom 0.001
Yes, definitely 254 (90.4) 159 (95.8) 95 (82.6)
Maybe 18 (6.4) 5 (3.0) 13 (11.3)
Definitely not 9 (3.2) 2 (1.2) 7 (6.1)
Afraid test will find lung cancer 0.042
(Continued )
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healthcare system due to poorer overall health and HIV status. Enthusiasm for tobacco cessation and
treatment and lung cancer screening with LDCT was also greater in the urban Johannesburg area
than in Kimberley; more participants were willing to quit smoking if told to do so by a physician
or if medication and support to quit were available, and to have lung cancer screening if the doctor
recommended it. The observed significant population differences in knowledge and attitudes suggest
that a ‘one size fits all’ type of intervention may not be effective and point to the need for tailored
approaches to outreach, engagement, and education for both patients and physicians to accompany
treatment interventions to decrease tobacco use.
Another important difference between the two locales is reported e-cigarette and vaping use.
Reported e-cigarette and vaping use in urban Johannesburg (65.4%) was double that in Kimberley
(35.2%). The 2016 South African Demographic and Health Survey (SADHS) reported that 2% of
women and 3% of men aged 15 years or older use e-cigarettes (National Department of Health
(NDoH), Statistics South Africa (Stats SA), South African Medical Research, & Council
(SAMRC), 2019). While SADHS was a population-based evaluation of e-cigarette use and ours
was an observational study of a small sample of current and former smokers who may be more likely
to use e-cigarettes, the difference in rates of e-cigarette use is staggering and supports alarms being
sounded by public health experts that e-cigarette use is increasing dramatically. Recent estimates pre-
dict that the e-cigarette market in South Africa, now $21 million annually, will nearly triple to $62
million by 2024 (PR Newswire, 2019). The major driver of this increase is the targeted marketing of
these products to youth in South Africa via on-line channels and social media in which e-cigarettes
are framed as an environmentally friendly, cost-effective, safe, convenient, and healthy alternative to
traditional tobacco smoking (PR Newswire, 2019). As the largest city in South Africa, Johannesburg
is the especially vulnerable to this type of intense marketing strategy. Governmental efforts to control
tobacco use have driven up the price of traditional cigarettes intentionally making them unaffordable
to larger numbers of individuals but therefore increasing the appeal of e-cigarettes (van Zyl-Smit,
2013). Additionally, the number of individuals suffering from serious illnesses associated with tra-
ditional tobacco consumption is increasing. Little is known about the potential harms of e-cigarettes
at this time (van Zyl-Smit, 2013). This lack of data allows e-cigarettes to be touted as a healthy sub-
stitute source of nicotine and means of treating nicotine addiction (van Zyl-Smit, 2013). Future
efforts to reduce tobacco use must therefore include educating the public about the uncertain safety
of e-cigarettes and the dangers of nicotine addiction associated with vaping.
Overall, 84.3% of study participants reported <30 pack-year history of cigarette smoking (number
of years smoked x cigarettes smoked per day). Current United States Preventive Services Task Force
(USPSTF) guidelines (United States Preventive Services Task Force, 2016) based on the findings of
the National Lung Screening Trial (NLST) (National Lung Screening Trial Research, et al., 2011) rec-
ommend annual LDCT lung cancer screening only for those at high risk for lung cancer on the basis
of age and smoking history – adults aged 55–80 years who have a minimum 30 pack-year smoking
history and currently smoke or have quit within the past 15 years (Jemal & Fedewa, 2017). This
Table 3. Continued.
Total (n = 324) Johannesburg (n = 182) Kimberley (n = 142) P value
Yes 70 (24.9) 34 (20.5) 36 (31.3)
No 203 (72.2) 129 (77.7) 74 (64.3)
Don’t know 8 (2.8) 3 (1.8) 5 (4.3)
Test will cause worry 0.009
Yes 150 (53.4) 93 (56.0) 57 (49.6)
No 114 (40.6) 69 (41.6) 45 (39.1)
Don’t know 17 (6.0) 4 (2.4) 13 (11.3)
Want to find lung cancer as early as possible if there 0.038
Yes 258 (91.8) 158 (95.2) 100 (87.0)
No 11 (3.9) 3 (1.8) 8 (7.0)
Don’t know 12 (4.3) 5 (3.0) 7 (6.1)
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targeted approach selects out ‘high risk’ individuals to maximise the benefits of screening while mini-
mising potential harms from false positive findings. Using NLST criteria, however, excludes most of
the individuals who participated in our study. This does not imply that South Africans are not at
greater risk, only that the risks to which South Africans in our study and those of other developing
countries (i.e. positive HIV status, co-infection with tuberculosis, and exposure to environmental
pollutants and toxins) were not evaluated in NLST therefore, the actual risk of this population
may not be reflected in NLST criteria. Clearly additional research is needed to define ‘high risk’
in this setting that accounts for the specific risks to which South Africans are exposed in order to
develop LDCT criteria that is relevant to these exposures and populations.
Further, because infrastructure to support widespread use screening with LDCT is not likely to be
developed in the near future in South Africa and other low-to-middle income and developing
countries and the research needed to define ‘high risk’ based on exposures not assessed in NLST
has not yet been conducted, resources and efforts in South Africa should be directed toward tobacco
cessation. Educating healthcare providers and supplying them with other tools to identify individuals
who smoke, creating infrastructure to support referrals to counselling, and making nicotine replace-
ment therapy available at little or no cost should be prioritised. Attention must be paid to the needs
of special segments of the population, including those who are HIV positive and those who have
tuberculosis – two conditions that are highly prevalent in South Africa. Two separate observational
studies conducted in Johannesburg at HIV clinics surveyed individuals with HIV infection (Shapiro
et al., 2011; Waweru et al., 2013), Each found high rates of tobacco use and a strong desire among
HIV-infected individuals to quit smoking. Both studies concluded that including tobacco treatment
in HIV care would be effective in assisting HIV-infected persons to quit smoking. Building upon this
work, a recent South African randomised trial compared intensive anti-smoking counselling with
counselling and nicotine replacement therapy among HIV-infected individuals found low rates of
cessation in both study arms (Krishnan et al., 2018). Post-hoc qualitative interviews of participants
and a focus group of counsellors revealed that multiple adverse social conditions, including stress,
discrimination, and low social support, contributed to tobacco addictive behaviour and undermined
the intervention. These findings suggestion that interventions to reduce tobacco use must also be
sensitive to the lived experience of the individual undergoing cessation counselling and should be
integrated into larger social support systems within healthcare organisations. In other words, a mul-
tilevel, coordinated approach is needed to address not only tobacco use behaviour but also the under-
lying determinants of this behaviour.
Our study has limitations that should be noted. It was an observational study conducted at two
geographic locations in South Africa. Both sites were part of a larger healthcare network and
affiliated with a Bristol Meyers Squib Foundation-funded grant to support lung health with trained
research staff. Thus, our findings may lack generalizability to other South African healthcare settings.
Our study participants had a history of smoking more than 100 cigarettes in their lifetime and were
seeking primary and lung disease care and may not be representative of all South African tobacco
smokers. Since medical charts are not maintained in the South African healthcare system in the
way they are in the United States (e.g. electronic medical records retained at the health facility),
comorbidity and environmental exposure data were self-reported. Inaccuracies in self-report may
have led to misclassification of existing chronic disease and toxic exposures.
The findings of our study demonstrate that smokers, both current and former, in two geographi-
cally distinct areas in South Africa are aware of the effects of tobacco smoking and other exposures as
risk factors for lung cancer and that smokers are receptive to tobacco cessation and lung cancer
screening efforts. That almost half of our study participants reported that they have never received
any advice or information on tobacco cessation from healthcare providers, indicates the need for a
concerted effort to train physicians and healthcare workers in tobacco addiction treatment. Further-
more, infrastructure to provide tobacco cessation should be sensitive to vulnerable patient popu-
lations, including those who are HIV-positive, and should include referral to care for the social
and other determinants of smoking behaviour. Efforts should also be made to counter the intensive
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marketing campaigns that promote e-cigarette use and vaping as safe, less expensive, and healthier
alternative sources of nicotine. Lastly, additional research is needed to assess ‘high risk’ criteria for
LDCT lung cancer screening in the context of the exposures common to developing countries, exam-
ine attitudes and knowledge of healthcare providers surrounding LDCT lung cancer screening, and
evaluate the feasibility and affordability of population-based LDCT as a means of decreasing lung
cancer mortality in South Africa.
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